Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$40.00 -0.2%	$35.80	$21.62 ▼ $41.71	$7.61B	1.1	2.51 million shs	3.26 million shs
BPMC Blueprint Medicines	$128.12 -0.1%	$102.85	$73.04 ▼ $128.34	$8.28B	0.84	1.24 million shs	3.48 million shs
CORT Corcept Therapeutics	$71.24 -0.8%	$71.43	$28.10 ▼ $117.33	$7.62B	0.19	1.14 million shs	907,284 shs
PRVB Provention Bio	$24.98	$24.58	$3.18 ▼ $25.00	$2.37B	2.47	2.28 million shs	218,200 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.17%	+2.43%	+18.73%	+17.96%	+44.88%
BPMC Blueprint Medicines	-0.09%	+0.13%	+26.59%	+44.82%	+20.06%
CORT Corcept Therapeutics	-0.85%	0.00%	-4.78%	+23.70%	+153.07%
PRVB Provention Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.7274 of 5 stars	4.5	2.0	0.0	3.9	3.8	3.3	0.6
BPMC Blueprint Medicines	1.2363 of 5 stars	2.1	2.0	0.0	0.0	2.7	0.8	0.6
CORT Corcept Therapeutics	4.6606 of 5 stars	3.5	1.0	0.0	4.2	3.2	4.2	1.9
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$56.67	41.67% Upside
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.05% Downside
CORT Corcept Therapeutics	3.00	Buy	$138.25	94.06% Upside
PRVB Provention Bio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PRVB, BPMC, CORT, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	34.23	N/A	N/A	($7.71) per share	-5.19
BPMC Blueprint Medicines	$508.82M	16.26	N/A	N/A	$4.70 per share	27.26
CORT Corcept Therapeutics	$675.04M	11.19	$1.23 per share	57.85	$6.49 per share	10.98
PRVB Provention Bio	$12.90M	183.54	N/A	N/A	$1.40 per share	17.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.11	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
CORT Corcept Therapeutics	$141.21M	$1.16	61.41	38.51	N/A	19.33%	20.40%	16.64%	8/4/2025 (Estimated)
PRVB Provention Bio	-$113.57M	-$1.53	N/A	N/A	N/A	-880.69%	-103.36%	-69.08%	N/A

Latest PRVB, BPMC, CORT, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
BPMC Blueprint Medicines	1.01	2.80	2.75
CORT Corcept Therapeutics	N/A	3.07	2.96
PRVB Provention Bio	0.19	1.93	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BPMC Blueprint Medicines	N/A
CORT Corcept Therapeutics	93.61%
PRVB Provention Bio	37.39%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BPMC Blueprint Medicines	4.21%
CORT Corcept Therapeutics	20.80%
PRVB Provention Bio	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
CORT Corcept Therapeutics	300	106.04 million	83.99 million	Optionable
PRVB Provention Bio	82	94.78 million	82.37 million	Not Optionable

PRVB, BPMC, CORT, and BBIO Headlines

Recent News About These Companies

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

March 9, 2025 | pharmaphorum.com

FDA rejects Provention's type 1 diabetes drug teplizumab

November 19, 2024 | pharmaphorum.com

Kimber Creek Ford

August 2, 2024 | cars.com

Ann Tricklebank Biography & Movies

May 25, 2024 | tribute.ca

VOA News

May 23, 2024 | voanews.com

Topic - Cumberland Valley School District

May 5, 2024 | washingtontimes.com

Macrogenics Inc MGNX

December 29, 2023 | morningstar.com

And for Wegovy's Next Trick, Full-Blown Cardiovascular Benefit Outside Diabetes

November 13, 2023 | medpagetoday.com

Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes

October 24, 2023 | nejm.org

FDA sets August decision date for Provention's type 1 diabetes drug

July 23, 2023 | pharmaphorum.com

Larry Pine Biography & Movies

June 27, 2023 | tribute.ca

Sanofi/Provention: innovative diabetes drug is a good fit

May 1, 2023 | finance.yahoo.com

Those who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%

April 29, 2023 | finance.yahoo.com

Sanofi completes Provention Bio acquisition

April 28, 2023 | seekingalpha.com

Sanofi concludes acquisition of Provention Bio

April 28, 2023 | medicaldialogues.in

Sanofi completes acquisition of Provention Bio, Inc.

April 28, 2023 | pharmiweb.com

Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline

April 27, 2023 | finance.yahoo.com

Sanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

April 27, 2023 | finanznachrichten.de

Provention Bio gains after HSR waiting period for Sanofi deal expired

April 26, 2023 | seekingalpha.com

Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

April 26, 2023 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRVB, BPMC, CORT, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$40.00 -0.07 (-0.17%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$40.01 +0.01 (+0.02%)

As of 06/18/2025 08:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Blueprint Medicines NASDAQ:BPMC

$128.12 -0.11 (-0.09%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$128.14 +0.02 (+0.02%)

As of 06/18/2025 07:11 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Corcept Therapeutics NASDAQ:CORT

$71.24 -0.61 (-0.85%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$71.28 +0.05 (+0.06%)

As of 06/18/2025 06:03 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Provention Bio NASDAQ:PRVB

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time